Corvus Pharmaceuticals (CRVS) Cash from Financing Activities (2015 - 2026)

Corvus Pharmaceuticals' Cash from Financing Activities history runs 11 years deep, the most recent figure standing at $190.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 68267.74% year-over-year to $190.7 million; the TTM figure through Mar 2026 stood at $226.9 million (up 1098.16% YoY), while the FY2025 annual figure was $36.4 million, down 25.7% from the prior year.
• Cash from Financing Activities was $190.7 million for Q1 2026 at Corvus Pharmaceuticals, up from $20000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $190.7 million in Q1 2026 to a low of $4000.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $25.4 million across 4 years, with a median of $347500.0 in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 99.89% in 2025, then surged 68267.74% in 2026.
• A 4-year view of Cash from Financing Activities shows it stood at $335000.0 in 2023, then jumped by 5454.63% to $18.6 million in 2024, then slumped by 99.89% to $20000.0 in 2025, then surged by 953630.0% to $190.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $190.7 million (Q1 2026), $20000.0 (Q4 2025), and $360000.0 (Q3 2025), per Business Quant data.